Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis

Inclusion Criteria: * At least two episodes of facial pain/pressure/fullness of moderate or severe intensity on a 4-point rating scale (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) in the past 30 days prior to the Screening Visit. * Subject agrees to study-required medication restrictions and the restriction of not starting new medication to treat CRS symptoms during the course of the study. * Subject agrees to study-required birth control methods during the course of the study, and female subjects must not be breastfeeding. * No clinically significant abnormality identified on the medical or laboratory evaluation. Exclusion Criteria: * Subject has primary headache disorder. * Subject has history of nasal or facial surgery within the 6 months prior to screening. * Subject has ongoing rhinitis medicamentosa. * Subject has diagnosed or suspected invasive fungal rhinosinusitis. * Subject is currently receiving aspirin desensitization or maintenance therapy for Samter's Triad. * Subject has a history of recurrent acute sinusitis (four or more episodes per year of acute bacterial rhinosinusitis (ABRS) without signs or symptoms of rhinosinusitis between episodes). * Body Mass Index \> 35.0kg/m2 * Subject history of exclusionary medical conditions such as HIV disease, cardiovascular conditions, uncontrolled hypertension or diabetes, psychiatric conditions, drug or alcohol abuse, malignancies, drug allergies, or any significant and/or unstable medical conditions. * Subjects taking/using excluded therapies. * Participation in clinical trial with non-biological investigational agents or investigational interventional treatments. * Subjects who have previously participated in any BHV-3000/ BMS-927711/ rimegepant study. * Planned participation in any other investigational clinical trial while participating in this clinical trial.